Biomarker for diagnosing polycystic ovarian syndrome and application thereof

By using circSPECC1(4) as a diagnostic biomarker for polycystic ovary syndrome (PCOS), and utilizing specific siRNA and detection methods, the issues of specificity and accuracy in the diagnosis of PCOS have been resolved, enabling rapid and accurate detection and differential diagnosis of PCOS.

CN122128423APending Publication Date: 2026-06-02NORTHERN JIANGSU PEOPLES HOSPITAL
0 Cites 0 Cited by

Patent Information

Application Number
CN202610299912.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-12
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Current technologies for diagnosing polycystic ovary syndrome (PCOS) lack objective, specific, and stable early diagnostic targets, leading to frequent missed diagnoses and misdiagnoses, making it difficult to achieve early screening and risk warning for the disease. Research on circular RNA in the diagnosis of PCOS is incomplete, and there is a lack of standardized detection systems.

Method used

circSPECC1(4) was used as a diagnostic biomarker. Its expression was knocked down by specific siRNA. The expression of circSPECC1(4) in ovarian granulosa cells or peripheral serum samples was detected by real-time quantitative PCR and fluorescence in situ hybridization. Specific primers and probes were designed to ensure the accuracy and specificity of the detection.

Benefits of technology

It provides a highly specific and stable diagnostic tool for polycystic ovary syndrome (PCOS), reducing the risk of missed diagnoses and misdiagnoses. It is suitable for invasive precision diagnosis and non-invasive initial screening, supports rapid and accurate detection and differential diagnosis of the disease, is applicable to a variety of clinical samples, and meets the needs of the entire process of PCOS diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and discloses a biomarker for diagnosing polycystic ovarian syndrome and application of the biomarker, the diagnostic biomarker is circSPECC1 (4), the circSPECC1 (4) is formed by reverse splicing cyclization of the fourth exon of an SPECC1 gene, the length of the circSPECC1 (4) is 1580 nt, and the circSPECC1 (4) has a closed circular RNA structure; the circSPECC1 (4) is specifically and highly expressed in ovarian granular cells of a patient with the polycystic ovarian syndrome, and mRNA expression levels of a female parent gene SPECC1 of the circSPECC1 (4) have no significant difference; the circSPECC1 (4) has RNaseR nuclease resistance stability, and is mainly positioned in cytoplasm; the expression of the circSPECC1 (4) is knocked down, so that the apoptosis of the ovarian granular cells can be obviously promoted, and the ovarian granular cell cycle is retarded at the G0 / G1 phase; according to the scheme, circSPECC1 (4) can be used as a specific diagnosis biomarker of the polycystic ovarian syndrome, structural characteristics, expression specificity and pathological regulation and control functions of the circular RNA are completely verified, and the blank that high-specificity and high-stability molecular diagnosis targets are lacked in the existing polycystic ovarian syndrome diagnosis field is filled.
Need to check novelty before this filing date? Find Prior Art